Risk factors for and outcomes of bacteremia caused by extended-spectrum β-lactamase- producing Escherichia coli and klebsiella species at a canadian tertiary care hospital

Canadian Journal of Hospital Pharmacy

Volumn 68, Issue 2, 2015, Pages 136-143

  Nguyen, My Linh ^a   Toye, Baldwin ^a,b   Kanji, Salmaan ^c   Zvonar, Rosemary ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Case control study; Extended spectrum lactamases; Klebsiella; Risk factors. Escherichia coli

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; QUINOLONE DERIVATIVE; TOBRAMYCIN;

ADULT; AGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BLADDER CATHETERIZATION; CANADIAN; CASE CONTROL STUDY; CENTRAL VENOUS CATHETERIZATION; CHARLSON COMORBIDITY INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; MORTALITY; NEOPLASM; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY CARE CENTER; TRAVEL; TREATMENT OUTCOME;

EID: 84957939938     PISSN: 00084123     EISSN: 19202903     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mazzulli T. Canadian patterns of antimicrobial resistance: overview of current trends related to hospital pathogens. Can J Infect Dis Med Microbiol. 2006;17 Suppl B:3B-5B.
2. Pitout JDD. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70(3):313-33.
3. Denisuik AJ, Lagacé-Wiens PRS, Pitout JD, Mulvey MR, Simmer PJ, Tailor F, et al. Molecular epidemiology of extended-spectrum ß-lactamase-, AmpC ß-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother. 2013;68 Suppl 1:i57-65.
4. Ofner-Agostini M, Simor A, Mulvey M, McGeer A, Hirji Z, McCracken M, et al. Risk factors for and outcomes associated with clinical isolates of Escherichia coli and Klebsiella species resistant to extended-spectrum cephalosporins among patients admitted to Canadian hospitals. Can J Infect Dis Med Microbiol. 2009;20(3):e43-8.
5. Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JDD. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect. 2008;57(6): 441-8.
6. Chaubey VP, Pitout JDD, Dalton B, Ross T, Church DL, Gregson DB, et al. Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes. 2010;3:116.
7. Performance standards for antimicrobial susceptibility testing (M100-S23): 23rd Informational Supplement. Wayne (PA): Clinical and Laboratory Standards Institute; 2013.
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
9. Aronoff GR, editor. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia (PA): American College of Physicians; 2007.
10. Repchinsky C, editor-in-chief. Compendium of pharmaceuticals and specialties. Ottawa (ON): Canadian Pharmacists Association; 2010.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
12. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Nashville (TN): Springer; 2001.
13. Ho PL, Chan WM, Tsang KT, Wong SS, Young K. Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: A case-control study of risk factors and outcomes. Scand J Infect Dis. 2002;34(8):567-73.
14. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extendedspectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49(5):682-90.
15. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruíz M, Peña C, et al. Community-onset bacteremia due to extended-spectrum beta-lactamaseproducing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010;50(1):40-8.
16. Silva N, Oliveira M, Bandeira AC, Brites C. Risk factors for infection by extended-spectrum beta-lactamase producing Klebsiella pneumoniae in a tertiary hospital in Salvador, Brazil. Braz J Infect Dis. 2006;10(3):191-3.
17. Kang CI, Kim SH, Kim DM, Park WB, Lee KD, Kim HB, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2004;25(10):860-7.
18. Kuster SP, Hasse B, Huebner V, Bansal V, Zbinden R, Ruef C, et al. Risk factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection. 2010;38(1):33-40.
19. Lee SO, Lee ES, Park SY, Seo YH, Cho YK. Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum betalactamase- producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2004;25(10):832-7.
20. Garnacho-Montero J, Garcia-Garmendia L, Barrero-Almodovar A, Jimenz- Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31(12):2742-51.
21. Tängdén T, Cars O, Melhus A, Löwdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: A prospective study with Swedish volunteers. Antimicrob Agents Chemother. 2010;54(9):3564-8.
22. Tham J, Odenholt I, Walder M, Brolund A, Ahl J, Melander E. Extendedspectrum beta-lactamase-producing Escherichia coli in patients with travellers' diarrhoea. Scand J Infect Dis. 2010;42(4):275-80.
23. Perez F, Bonomo RA. Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria? Clin Infect Dis. 2012;54(2):175-7.
24. External quality assessment: Bacteriology. Consensus practice recommendations - antimicrobial susceptibility testing and reporting on bacteriology specimens. Toronto (ON): Quality Management Program-Laboratory Services; 2007 Nov 11 [revised 2013 May 29].
25. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extendedspectrum- beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50(4):1257-62.
26. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(5):913-20.
27. Kang CI, Song JH, Chung DR, Peck KR, Ko KS, Yeom JS, et al.; Korean Network for Study of Infectious Diseases (KONSID). Risk factors and treatment outcomes of community-onset bacteraemia caused by extendedspectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents. 2010;36(3):284-7.
28. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: A matched cohort study. Infect Control Hosp Epidemiol. 2006;27(11):1226-32.
29. Frakking FNJ, Rottier WC, Dorigo-Zetsma JW, van Hattem JM, van Hees BC, Kluytmans JAJW, et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-ß-lactamase-producing bacteria. Antimicrob Agents Chemother. 2013;57(7):3092-9.